ArticleNature communications2024

Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy.

Jingjing Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.